2022 GEM rise biomedical innovation highland (with shares)
On the one hand, it is designated as a key strategic cultivation industry by countries around the world, on the other hand, the incubation and cultivation of the difficulty, the cycle is long, the risk is high, how to find the focus point to promote the high-quality development of biomedicine? So today I am here to organize the knowledge of biomedicine, let's take a look together!
Let the "fit" deepen once
Large investment, high risk, long cycle, these are the biomedical industry as the representative of the development of high-tech industries face challenges. To promote the development of high-tech industries, the need for efficient flow of innovative elements, to release its potential; and "pull one hair and affect the whole body" of the capital market is the best hub for the deployment of resources.
Kemena is China's first self-developed small molecule targeted anticancer drug, and its R & D producer is the GEM biopharmaceutical company - Beida Pharmaceuticals.
In June 2021, Kemena was approved to be listed in the postoperative adjuvant therapy indication, and was successfully included in the national health insurance catalog at the end of the year. Kemena has been on the market for 11 years, and has exceeded 1 billion yuan in sales for six consecutive years, with cumulative sales of more than 10 billion yuan, benefiting 320,000 patients with advanced lung cancer. In addition to Kemena, Beda Pharmaceuticals has two other marketed products, Bemena and Beantin, five drugs in late-stage clinical studies or have submitted marketing applications, as well as more than 40 research and development programs in the pipeline.
"The rich R&D pipeline has provided the company with a steady stream of vitality, and in 2021 the company's annual revenue exceeded 2 billion yuan for the first time, reaching 2.246 billion yuan, a year-on-year increase of 20.08 percent." Wu Fei, director of the chairman's office of Beida Pharmaceuticals, in an interview with a reporter from the Securities Times.
Wu Fei said, GEM fully match the positioning of the service innovation and entrepreneurial enterprises, understand and meet the financing needs of enterprises at all stages of the development process; GEM provides an active capital market platform for enterprises to enhance the visibility of the enterprise and the social image; GEM very innovative service spirit, in-depth understanding of the needs of the enterprise, for the stage of development of the enterprise, enterprise characteristics of the development of more targeted The GEM has a very innovative service spirit, and understands the needs of enterprises in depth, and formulates more targeted service measures and regulatory policies for the development stage and characteristics of enterprises, so as to effectively solve the difficulties of enterprises, and improve the effectiveness of corporate governance and information disclosure.
Relying on the GEM, Beida Pharmaceuticals continues to break through, which is a perfect example of how the capital market and high-tech industries are naturally "compatible". As a gathering place for innovative enterprises, the GEM has deepened the fit between the two through continuous reform and innovation, empowering scientific and technological innovation.
In recent years, around the main line of the registration system, the GEM board to promote the issue of underwriting, listing, trading, continuous supervision, delisting, investor protection and a series of basic system reforms. 2021 is the reform of the GEM board and the pilot registration system after the landing of the first full-year. 2021 GEM companies R & D investment **** totaled 136,125,000,000 yuan, a year-on-year increase of 29.08%. The average R&D investment of newly listed companies under the registration system increased by 37.29% year-on-year. Up to now, 90% of GEM companies are high-tech enterprises, and 80% have patented technologies related to their main products.
Coalescing innovation into an ecology
"R&D innovation and technology upgrading is the permanent lifeline of a medical device company, and over the years, the company has insisted on investing about 10 percent of its revenue in R&D every year." Myriad Medical secretary Li Wenfang told reporters about the key to the company's development and growth: "The company's rapid growth in revenue volume in the process of maintaining a high investment in R & D is the core of the company's endogenous growth perennial and robust."
Li Wenfang introduced, by the end of 2021 the company has about 3,500 R & D engineers, accumulated more than 7,400 patents reserves, including more than 5,300 invention patents.
Medicine has gradually transformed itself from a supplier of medical devices into a solution provider that enhances the overall diagnosis and treatment capability of medical institutions, established a R&D and innovation platform based on global resource allocation, and formed a huge globalized R&D, marketing and service network. Up to now, the company's total market capitalization has exceeded 350 billion yuan.
Innovation to lead the core competitiveness of the GEM biomedical enterprises, similar to the Myriad Medical example there are many.
In the field of biopharmaceuticals, Zhifei Biological adhere to innovation as the driving force, there are currently 29 independent research and development pipeline, the formation of tuberculosis, rabies, respiratory viruses, pneumonia, intestinal diseases and meningitis and many other product categories.
Watson Biologicals, in terms of R&D and innovation, benchmarks the global layout of the biopharmaceutical industry's cutting-edge technology, has been listed on the eight personal vaccine products (12 specifications) are self-developed and produced, of which, the self-developed "13-valent Pneumococcal Polysaccharide Conjugate Vaccine" is the first of its kind in China to fill the domestic gaps of pneumonia vaccine, successfully realizing import substitution, and providing a good opportunity for the domestic pneumococcal vaccine market. The company has successfully realized import substitution and laid the foundation for the research and development of domestic pneumonia vaccine.
In the field of pharmaceutical technology R&D services, Tigermed is the first domestic CRO (pharmaceutical R&D contract outsourcing service provider) to take the lead in the global expansion of the pioneer, by the end of 2021, the company has more than 1,000 professional team in more than 50 countries overseas, 132 single-region clinical trials, 50 multi-region clinical trials, involving the therapeutic areas of oncology, vaccines, central nervous system, and other areas of the world, and the company is also a leader in the field of clinical trials. , vaccines, central nervous system, cardiovascular diseases and rare diseases.
Planting sycamore trees attracts phoenixes. As of the end of July 2022,*** 96 biomedical enterprises were listed on the GEM, accounting for nearly 60% of the number of biomedical enterprises in Shenzhen, with a total market capitalization of 1.73 trillion yuan, covering the whole industrial chain system from chemical pharmaceuticals to Chinese medicine tablets, from genetic testing to in vitro diagnostics, from bio-vaccines to blood products, and from medical devices to healthcare services, etc.
We are pleased to announce that we will continue our efforts to promote the development of biopharmaceutical industry in China.
What are the leading stocks of biomedical concept
Zoli Pharmaceuticals 300181
Zhejiang Zoli Pharmaceuticals Co., Ltd. main business for the medicinal fungi wuling and Bailing series of products, traditional Chinese medicine tablets and traditional Chinese medicine formula particles of the research and development, production and sales. The company's main products include Wuling series and Bailing tablets, Chinese medicine tablets and Chinese medicine formula granules.
Heavy Pharmaceuticals Holding Company Limited 000950
Heavy Pharmaceuticals Holding Company Limited is principally engaged in the pharmaceutical distribution business. Based on the synergistic development of pharmaceutical business and pharmaceutical research and development, the company is a leading pharmaceutical and health industry group in the west. The company's main products are pharmaceuticals and medical devices.
Zhongsheng Pharmaceutical 002317
Guangdong Zhongsheng Pharmaceutical Co. Ltd. is mainly engaged in pharmaceutical research and development, production and sales.
Zhongyuan Xiehe 600645
Zhongyuan Xiehe Cellular Genetic Engineering Co., Ltd. is a biotechnology company, the company is mainly engaged in the development of life science and technology, the industrialization of stem cell genetic engineering, biomedicine and gene pharmaceuticals, textile, printing and dyeing, clothing and other businesses. Its main products include cell detection preparation and storage, research reagents, gene detection and testing reagents.